or Try an Advanced Search...

    Technical Analysis for LXEO - Lexeo Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 11.50 -2.46% -0.29
    LXEO closed down 2.46 percent on Friday, July 26, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent N/A Down Down
    Historical LXEO trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Narrow Range Bar Range Contraction -2.46%
    Wide Bands Range Expansion -2.46%
    Oversold Stochastic Weakness -2.46%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.71%
    NR7 Range Contraction -2.71%
    Narrow Range Bar Range Contraction -2.71%
    Inside Day Range Contraction -2.71%
    Wide Bands Range Expansion -2.71%
    Older End-of-Day Signals for LXEO ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 12 hours ago
    1.5x Volume Pace about 13 hours ago
    Fell Below Previous Day's Low about 13 hours ago
    Down 2 % about 13 hours ago
    60 Minute Opening Range Breakdown about 13 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    LXEO Chart by TradingView
    Basic chart:

    Profile

    Lexeo Therapeutics, Inc. Description

    Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Disease Rare Diseases Gene Therapy Applied Genetics Cardiomyopathy Lipid Storage Disorders Ataxia Friedreich's Ataxia

    Is LXEO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 18 Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
    Jul 16 Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
    Jul 16 Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
    Jul 15 Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder
    Jul 15 Lexeo stock drops 24% amid Friedreich Ataxia study results
    Jul 15 Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
    Jul 15 Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers
    Jul 15 Lexeo gene therapy shows signs of heart benefit in small study
    Jul 15 Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
    Jul 11 Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
    See more LXEO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.33
    52 Week Low 9.0
    Average Volume 309,373
    200-Day Moving Average 0.00
    50-Day Moving Average 15.23
    20-Day Moving Average 13.92
    10-Day Moving Average 11.77
    Average True Range 1.22
    RSI (14) 35.90
    ADX 18.07
    +DI 23.26
    -DI 30.16
    Chandelier Exit (Long, 3 ATRs) 15.83
    Chandelier Exit (Short, 3 ATRs) 14.57
    Upper Bollinger Bands 18.54
    Lower Bollinger Band 9.29
    Percent B (%b) 0.24
    BandWidth 66.41
    MACD Line -1.20
    MACD Signal Line -0.93
    MACD Histogram -0.2742
    Fundamentals Value
    Market Cap 306.42 Million
    Num Shares 26.6 Million
    EPS
    Price-to-Sales 0.00
    Price-to-Book 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.54
    Resistance 3 (R3) 12.60 12.33 12.36
    Resistance 2 (R2) 12.33 12.06 12.29 12.30
    Resistance 1 (R1) 11.91 11.90 11.78 11.85 12.25
    Pivot Point 11.64 11.64 11.57 11.60 11.64
    Support 1 (S1) 11.22 11.37 11.09 11.16 10.75
    Support 2 (S2) 10.95 11.21 10.91 10.70
    Support 3 (S3) 10.53 10.95 10.64
    Support 4 (S4) 10.47